Accretion Pharmaceuticals Ltd (ACCPL) is currently trading at 182.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Accretion Pharmaceuticals Limited is a Gujarat-headquartered manufacturer and CDMO of generic and branded pharmaceutical formulations across tablets, capsules, oral liquids, powders and external preparations, operating a WHO‑cGMP certified, multi‑dosage manufacturing facility focused on domestic sales, loan‑license production and exports to 30+ countries. Financial momentum accelerated in FY26 with total income of ₹89.63 crore, a 56.21% YoY increase, and Profit After Tax of ₹9.67 crore, up 42.30% YoY. EBITDA was ₹14.95 crore with a 16.68% margin, reflecting growth but some margin compression due to product mix and upfront registration and compliance investments. Export‑led strategy and international reach are central: Accretion exports to over 30 countries across Africa, Southeast Asia and Latin America, has a merchant exporter network exceeding 70 entities, and is intentionally shifting from merchant exports to direct market engagement to capture higher margins and deeper customer relationships. Operational footprint demonstrates scale and compliance: the Ahmedabad plant reports installed capacity of 1,635 million units across dosage forms, multiple ISO certifications and WHO‑cGMP approval, and the company emphasizes capacity utilisation gains, QC infrastructure (HPLC, micro labs) and continuous manufacturing improvements to support CDMO growth. Capital structure and liquidity show improvement after the May 2025 equity raise (29.46 lakh shares raising ~₹29.75 crore), with a conservative balance sheet in FY26 (Net debt to equity ~0.15) and reported ROCE above 20%, providing some firepower for registrations, direct market expansion and targeted capex.

Over the past 52 weeks, Accretion Pharmaceuticals Ltd has traded between a low of ₹54.60 and a high of ₹220.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Accretion Pharmaceuticals Ltd has a market capitalization of approximately 202.42. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Accretion Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.93 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 202.42 Cr, Accretion Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Accretion Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Accretion Pharmaceuticals Ltd is 20.93. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.